Gaillard, S., Oaknin, A., Ray-Coquard, I. L., Vergote, I. B., Scambia, G., Colombo, N., … Lorusso, D. (2018). Phase III trial of lurbinectedin versus PLD or topotecan in platinum-resistant ovarian cancer patients: Results of CORAIL trial. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 29, viii332. https://doi.org/10.1093/annonc/mdy285

Gaillard, S., A. Oaknin, I. L. Ray-Coquard, I. B. Vergote, G. Scambia, N. Colombo, S. A. Ghamande, et al. “Phase III trial of lurbinectedin versus PLD or topotecan in platinum-resistant ovarian cancer patients: Results of CORAIL trial.” Annals of Oncology : Official Journal of the European Society for Medical Oncology 29 (October 1, 2018): viii332. https://doi.org/10.1093/annonc/mdy285.

Gaillard S, Oaknin A, Ray-Coquard IL, Vergote IB, Scambia G, Colombo N, et al. Phase III trial of lurbinectedin versus PLD or topotecan in platinum-resistant ovarian cancer patients: Results of CORAIL trial. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii332.

Gaillard, S., et al. “Phase III trial of lurbinectedin versus PLD or topotecan in platinum-resistant ovarian cancer patients: Results of CORAIL trial.” Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 29, Oct. 2018, p. viii332. Scopus, doi:10.1093/annonc/mdy285.

Gaillard S, Oaknin A, Ray-Coquard IL, Vergote IB, Scambia G, Colombo N, Ghamande SA, Soto-Matos A, Fernandez CM, Kahatt C, Gomez J, Nieto A, Torres N, Pardo-Burdalo B, Papai Z, Kristeleit RS, O’Malley DM, Benjamin I, Pautier P, Lorusso D. Phase III trial of lurbinectedin versus PLD or topotecan in platinum-resistant ovarian cancer patients: Results of CORAIL trial. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii332.